Skip to contents

(Deprecated, use dfTrials2Long and dfName2Value!) The function uses a name (key) to extract an element from a list in a data.frame such as obtained with dbGetFieldsIntoDf. This helps to simplify working with nested lists and with complex structures.

Usage

dfListExtractKey(df, list.key = list(c("endPoints.endPoint", "^title")))

Arguments

df

A data frame (or tibble)

list.key

A list of pairs of list names and key names, where the list name corresponds to the name of a column in df that holds a list and the name of the key identifies the element to be extracted. See example.

Value

A data frame (or tibble, if dplyr is loaded) in long format with columns name (identifying the full path in the data frame, "<list>.<key>"), _id (of the trial record), value (of name per _id), item (number of value of name per _id).

Examples


dbc <- nodbi::src_sqlite(
   dbname = system.file("extdata", "demo.sqlite", package = "ctrdata"),
   collection = "my_trials")

df <- dbGetFieldsIntoDf(
  fields = c(
    "endPoints.endPoint",
    "subjectDisposition.postAssignmentPeriods"),
  con = dbc)
#> endPoints.endPoint... 
#>     
#> . 
#> 
#> subjectDisposition.postAssignmentPeriods... 
#>     
#> . 

suppressWarnings(
  dfListExtractKey(
    df = df,
    list.key = list(
        c("endPoints.endPoint",
          "^title"),
        c("subjectDisposition.postAssignmentPeriods",
          "arms.arm.type.value"))
))
#>                         name               _id
#> 1   endPoints.endPoint.title 2012-003632-23-AT
#> 2   endPoints.endPoint.title 2012-003632-23-AT
#> 3   endPoints.endPoint.title 2012-003632-23-AT
#> 4   endPoints.endPoint.title 2012-003632-23-AT
#> 5   endPoints.endPoint.title 2012-003632-23-AT
#> 6   endPoints.endPoint.title 2012-003632-23-AT
#> 7   endPoints.endPoint.title 2012-003632-23-AT
#> 8   endPoints.endPoint.title 2012-003632-23-AT
#> 9   endPoints.endPoint.title 2012-003632-23-CZ
#> 10  endPoints.endPoint.title 2012-003632-23-CZ
#> 11  endPoints.endPoint.title 2012-003632-23-CZ
#> 12  endPoints.endPoint.title 2012-003632-23-CZ
#> 13  endPoints.endPoint.title 2012-003632-23-CZ
#> 14  endPoints.endPoint.title 2012-003632-23-CZ
#> 15  endPoints.endPoint.title 2012-003632-23-CZ
#> 16  endPoints.endPoint.title 2012-003632-23-CZ
#> 17  endPoints.endPoint.title 2012-003632-23-DE
#> 18  endPoints.endPoint.title 2012-003632-23-DE
#> 19  endPoints.endPoint.title 2012-003632-23-DE
#> 20  endPoints.endPoint.title 2012-003632-23-DE
#> 21  endPoints.endPoint.title 2012-003632-23-DE
#> 22  endPoints.endPoint.title 2012-003632-23-DE
#> 23  endPoints.endPoint.title 2012-003632-23-DE
#> 24  endPoints.endPoint.title 2012-003632-23-DE
#> 25  endPoints.endPoint.title 2012-003632-23-ES
#> 26  endPoints.endPoint.title 2012-003632-23-ES
#> 27  endPoints.endPoint.title 2012-003632-23-ES
#> 28  endPoints.endPoint.title 2012-003632-23-ES
#> 29  endPoints.endPoint.title 2012-003632-23-ES
#> 30  endPoints.endPoint.title 2012-003632-23-ES
#> 31  endPoints.endPoint.title 2012-003632-23-ES
#> 32  endPoints.endPoint.title 2012-003632-23-ES
#> 33  endPoints.endPoint.title 2012-003632-23-GB
#> 34  endPoints.endPoint.title 2012-003632-23-GB
#> 35  endPoints.endPoint.title 2012-003632-23-GB
#> 36  endPoints.endPoint.title 2012-003632-23-GB
#> 37  endPoints.endPoint.title 2012-003632-23-GB
#> 38  endPoints.endPoint.title 2012-003632-23-GB
#> 39  endPoints.endPoint.title 2012-003632-23-GB
#> 40  endPoints.endPoint.title 2012-003632-23-GB
#> 41  endPoints.endPoint.title 2012-003632-23-IT
#> 42  endPoints.endPoint.title 2012-003632-23-IT
#> 43  endPoints.endPoint.title 2012-003632-23-IT
#> 44  endPoints.endPoint.title 2012-003632-23-IT
#> 45  endPoints.endPoint.title 2012-003632-23-IT
#> 46  endPoints.endPoint.title 2012-003632-23-IT
#> 47  endPoints.endPoint.title 2012-003632-23-IT
#> 48  endPoints.endPoint.title 2012-003632-23-IT
#> 49  endPoints.endPoint.title 2012-003632-23-SE
#> 50  endPoints.endPoint.title 2012-003632-23-SE
#> 51  endPoints.endPoint.title 2012-003632-23-SE
#> 52  endPoints.endPoint.title 2012-003632-23-SE
#> 53  endPoints.endPoint.title 2012-003632-23-SE
#> 54  endPoints.endPoint.title 2012-003632-23-SE
#> 55  endPoints.endPoint.title 2012-003632-23-SE
#> 56  endPoints.endPoint.title 2012-003632-23-SE
#> 57  endPoints.endPoint.title 2013-005512-10-DE
#> 58  endPoints.endPoint.title 2013-005512-10-DE
#> 59  endPoints.endPoint.title 2013-005512-10-DE
#> 60  endPoints.endPoint.title 2013-005512-10-DE
#> 61  endPoints.endPoint.title 2013-005512-10-DE
#> 62  endPoints.endPoint.title 2013-005512-10-DE
#> 63  endPoints.endPoint.title 2013-005512-10-DE
#> 64  endPoints.endPoint.title 2013-005512-10-DE
#> 65  endPoints.endPoint.title 2013-005512-10-DE
#> 66  endPoints.endPoint.title 2013-005512-10-DE
#> 67  endPoints.endPoint.title 2013-005512-10-DK
#> 68  endPoints.endPoint.title 2013-005512-10-DK
#> 69  endPoints.endPoint.title 2013-005512-10-DK
#> 70  endPoints.endPoint.title 2013-005512-10-DK
#> 71  endPoints.endPoint.title 2013-005512-10-DK
#> 72  endPoints.endPoint.title 2013-005512-10-DK
#> 73  endPoints.endPoint.title 2013-005512-10-DK
#> 74  endPoints.endPoint.title 2013-005512-10-DK
#> 75  endPoints.endPoint.title 2013-005512-10-DK
#> 76  endPoints.endPoint.title 2013-005512-10-DK
#> 77  endPoints.endPoint.title 2013-005512-10-ES
#> 78  endPoints.endPoint.title 2013-005512-10-ES
#> 79  endPoints.endPoint.title 2013-005512-10-ES
#> 80  endPoints.endPoint.title 2013-005512-10-ES
#> 81  endPoints.endPoint.title 2013-005512-10-ES
#> 82  endPoints.endPoint.title 2013-005512-10-ES
#> 83  endPoints.endPoint.title 2013-005512-10-ES
#> 84  endPoints.endPoint.title 2013-005512-10-ES
#> 85  endPoints.endPoint.title 2013-005512-10-ES
#> 86  endPoints.endPoint.title 2013-005512-10-ES
#> 87  endPoints.endPoint.title 2013-005512-10-FR
#> 88  endPoints.endPoint.title 2013-005512-10-FR
#> 89  endPoints.endPoint.title 2013-005512-10-FR
#> 90  endPoints.endPoint.title 2013-005512-10-FR
#> 91  endPoints.endPoint.title 2013-005512-10-FR
#> 92  endPoints.endPoint.title 2013-005512-10-FR
#> 93  endPoints.endPoint.title 2013-005512-10-FR
#> 94  endPoints.endPoint.title 2013-005512-10-FR
#> 95  endPoints.endPoint.title 2013-005512-10-FR
#> 96  endPoints.endPoint.title 2013-005512-10-FR
#> 97  endPoints.endPoint.title 2013-005512-10-GB
#> 98  endPoints.endPoint.title 2013-005512-10-GB
#> 99  endPoints.endPoint.title 2013-005512-10-GB
#> 100 endPoints.endPoint.title 2013-005512-10-GB
#> 101 endPoints.endPoint.title 2013-005512-10-GB
#> 102 endPoints.endPoint.title 2013-005512-10-GB
#> 103 endPoints.endPoint.title 2013-005512-10-GB
#> 104 endPoints.endPoint.title 2013-005512-10-GB
#> 105 endPoints.endPoint.title 2013-005512-10-GB
#> 106 endPoints.endPoint.title 2013-005512-10-GB
#> 107 endPoints.endPoint.title 2013-005512-10-IE
#> 108 endPoints.endPoint.title 2013-005512-10-IE
#> 109 endPoints.endPoint.title 2013-005512-10-IE
#> 110 endPoints.endPoint.title 2013-005512-10-IE
#> 111 endPoints.endPoint.title 2013-005512-10-IE
#> 112 endPoints.endPoint.title 2013-005512-10-IE
#> 113 endPoints.endPoint.title 2013-005512-10-IE
#> 114 endPoints.endPoint.title 2013-005512-10-IE
#> 115 endPoints.endPoint.title 2013-005512-10-IE
#> 116 endPoints.endPoint.title 2013-005512-10-IE
#> 117 endPoints.endPoint.title 2013-005512-10-IT
#> 118 endPoints.endPoint.title 2013-005512-10-IT
#> 119 endPoints.endPoint.title 2013-005512-10-IT
#> 120 endPoints.endPoint.title 2013-005512-10-IT
#> 121 endPoints.endPoint.title 2013-005512-10-IT
#> 122 endPoints.endPoint.title 2013-005512-10-IT
#> 123 endPoints.endPoint.title 2013-005512-10-IT
#> 124 endPoints.endPoint.title 2013-005512-10-IT
#> 125 endPoints.endPoint.title 2013-005512-10-IT
#> 126 endPoints.endPoint.title 2013-005512-10-IT
#> 127 endPoints.endPoint.title 2013-005512-10-NL
#> 128 endPoints.endPoint.title 2013-005512-10-NL
#> 129 endPoints.endPoint.title 2013-005512-10-NL
#> 130 endPoints.endPoint.title 2013-005512-10-NL
#> 131 endPoints.endPoint.title 2013-005512-10-NL
#> 132 endPoints.endPoint.title 2013-005512-10-NL
#> 133 endPoints.endPoint.title 2013-005512-10-NL
#> 134 endPoints.endPoint.title 2013-005512-10-NL
#> 135 endPoints.endPoint.title 2013-005512-10-NL
#> 136 endPoints.endPoint.title 2013-005512-10-NL
#> 137 endPoints.endPoint.title 2013-005512-10-PL
#> 138 endPoints.endPoint.title 2013-005512-10-PL
#> 139 endPoints.endPoint.title 2013-005512-10-PL
#> 140 endPoints.endPoint.title 2013-005512-10-PL
#> 141 endPoints.endPoint.title 2013-005512-10-PL
#> 142 endPoints.endPoint.title 2013-005512-10-PL
#> 143 endPoints.endPoint.title 2013-005512-10-PL
#> 144 endPoints.endPoint.title 2013-005512-10-PL
#> 145 endPoints.endPoint.title 2013-005512-10-PL
#> 146 endPoints.endPoint.title 2013-005512-10-PL
#> 147 endPoints.endPoint.title 2013-005512-10-SE
#> 148 endPoints.endPoint.title 2013-005512-10-SE
#> 149 endPoints.endPoint.title 2013-005512-10-SE
#> 150 endPoints.endPoint.title 2013-005512-10-SE
#> 151 endPoints.endPoint.title 2013-005512-10-SE
#> 152 endPoints.endPoint.title 2013-005512-10-SE
#> 153 endPoints.endPoint.title 2013-005512-10-SE
#> 154 endPoints.endPoint.title 2013-005512-10-SE
#> 155 endPoints.endPoint.title 2013-005512-10-SE
#> 156 endPoints.endPoint.title 2013-005512-10-SE
#> 157 endPoints.endPoint.title 2014-003556-31-GB
#> 158 endPoints.endPoint.title 2014-003556-31-GB
#> 159 endPoints.endPoint.title 2014-003556-31-GB
#> 160 endPoints.endPoint.title 2014-003556-31-GB
#> 161 endPoints.endPoint.title 2014-003556-31-GB
#> 162 endPoints.endPoint.title 2014-003556-31-GB
#> 163 endPoints.endPoint.title 2014-003556-31-GB
#> 164 endPoints.endPoint.title 2014-003556-31-GB
#> 165 endPoints.endPoint.title 2014-003556-31-GB
#> 166 endPoints.endPoint.title 2014-003556-31-GB
#> 167 endPoints.endPoint.title 2014-003556-31-GB
#> 168 endPoints.endPoint.title 2014-003556-31-GB
#> 169 endPoints.endPoint.title 2014-003556-31-GB
#> 170 endPoints.endPoint.title 2014-003556-31-GB
#> 171 endPoints.endPoint.title 2014-003556-31-GB
#> 172 endPoints.endPoint.title 2014-003556-31-GB
#> 173 endPoints.endPoint.title 2014-003556-31-GB
#> 174 endPoints.endPoint.title 2014-003556-31-GB
#> 175 endPoints.endPoint.title 2014-003556-31-GB
#> 176 endPoints.endPoint.title 2014-003556-31-GB
#> 177 endPoints.endPoint.title 2014-003556-31-GB
#> 178 endPoints.endPoint.title 2014-003556-31-GB
#> 179 endPoints.endPoint.title 2014-003556-31-GB
#> 180 endPoints.endPoint.title 2014-003556-31-GB
#> 181 endPoints.endPoint.title 2014-003556-31-GB
#> 182 endPoints.endPoint.title 2014-003556-31-GB
#> 183 endPoints.endPoint.title 2014-003556-31-GB
#> 184 endPoints.endPoint.title 2014-003556-31-GB
#> 185 endPoints.endPoint.title 2014-003556-31-GB
#> 186 endPoints.endPoint.title 2014-003556-31-GB
#> 187 endPoints.endPoint.title 2014-003556-31-GB
#> 188 endPoints.endPoint.title 2014-003556-31-GB
#> 189 endPoints.endPoint.title 2014-003556-31-GB
#> 190 endPoints.endPoint.title 2014-003556-31-GB
#> 191 endPoints.endPoint.title 2014-003556-31-GB
#> 192 endPoints.endPoint.title 2014-003556-31-GB
#> 193 endPoints.endPoint.title 2014-003556-31-GB
#> 194 endPoints.endPoint.title 2014-003556-31-GB
#> 195 endPoints.endPoint.title 2014-003556-31-GB
#> 196 endPoints.endPoint.title 2014-003556-31-GB
#> 197 endPoints.endPoint.title 2014-003556-31-IT
#> 198 endPoints.endPoint.title 2014-003556-31-IT
#> 199 endPoints.endPoint.title 2014-003556-31-IT
#> 200 endPoints.endPoint.title 2014-003556-31-IT
#> 201 endPoints.endPoint.title 2014-003556-31-IT
#> 202 endPoints.endPoint.title 2014-003556-31-IT
#> 203 endPoints.endPoint.title 2014-003556-31-IT
#> 204 endPoints.endPoint.title 2014-003556-31-IT
#> 205 endPoints.endPoint.title 2014-003556-31-IT
#> 206 endPoints.endPoint.title 2014-003556-31-IT
#> 207 endPoints.endPoint.title 2014-003556-31-IT
#> 208 endPoints.endPoint.title 2014-003556-31-IT
#> 209 endPoints.endPoint.title 2014-003556-31-IT
#> 210 endPoints.endPoint.title 2014-003556-31-IT
#> 211 endPoints.endPoint.title 2014-003556-31-IT
#> 212 endPoints.endPoint.title 2014-003556-31-IT
#> 213 endPoints.endPoint.title 2014-003556-31-IT
#> 214 endPoints.endPoint.title 2014-003556-31-IT
#> 215 endPoints.endPoint.title 2014-003556-31-IT
#> 216 endPoints.endPoint.title 2014-003556-31-IT
#> 217 endPoints.endPoint.title 2014-003556-31-IT
#> 218 endPoints.endPoint.title 2014-003556-31-IT
#> 219 endPoints.endPoint.title 2014-003556-31-IT
#> 220 endPoints.endPoint.title 2014-003556-31-IT
#> 221 endPoints.endPoint.title 2014-003556-31-IT
#> 222 endPoints.endPoint.title 2014-003556-31-IT
#> 223 endPoints.endPoint.title 2014-003556-31-IT
#> 224 endPoints.endPoint.title 2014-003556-31-IT
#> 225 endPoints.endPoint.title 2014-003556-31-IT
#> 226 endPoints.endPoint.title 2014-003556-31-IT
#> 227 endPoints.endPoint.title 2014-003556-31-IT
#> 228 endPoints.endPoint.title 2014-003556-31-IT
#> 229 endPoints.endPoint.title 2014-003556-31-IT
#> 230 endPoints.endPoint.title 2014-003556-31-IT
#> 231 endPoints.endPoint.title 2014-003556-31-IT
#> 232 endPoints.endPoint.title 2014-003556-31-IT
#> 233 endPoints.endPoint.title 2014-003556-31-IT
#> 234 endPoints.endPoint.title 2014-003556-31-IT
#> 235 endPoints.endPoint.title 2014-003556-31-IT
#> 236 endPoints.endPoint.title 2014-003556-31-IT
#> 237 endPoints.endPoint.title 2014-003556-31-NL
#> 238 endPoints.endPoint.title 2014-003556-31-NL
#> 239 endPoints.endPoint.title 2014-003556-31-NL
#> 240 endPoints.endPoint.title 2014-003556-31-NL
#> 241 endPoints.endPoint.title 2014-003556-31-NL
#> 242 endPoints.endPoint.title 2014-003556-31-NL
#> 243 endPoints.endPoint.title 2014-003556-31-NL
#> 244 endPoints.endPoint.title 2014-003556-31-NL
#> 245 endPoints.endPoint.title 2014-003556-31-NL
#> 246 endPoints.endPoint.title 2014-003556-31-NL
#> 247 endPoints.endPoint.title 2014-003556-31-NL
#> 248 endPoints.endPoint.title 2014-003556-31-NL
#> 249 endPoints.endPoint.title 2014-003556-31-NL
#> 250 endPoints.endPoint.title 2014-003556-31-NL
#>                                                                                                                                                                       value
#> 1                                                                                                                                                  Time to Overall Response
#> 2                                                                                                                                              Durability of First Response
#> 3                                                                                                                                                     Glucocortoid Tapering
#> 4                                                                                                                                                         Survival Pre-HSCT
#> 5                                                                                                                                                          Overall Survival
#> 6                                                                                                                                                          Overall Response
#> 7                                                                                                                                                        Survival Post-HSCT
#> 8                                                                                                                                           Cumulative Duration of Response
#> 9                                                                                                                                                  Time to Overall Response
#> 10                                                                                                                                             Durability of First Response
#> 11                                                                                                                                                    Glucocortoid Tapering
#> 12                                                                                                                                                        Survival Pre-HSCT
#> 13                                                                                                                                                         Overall Survival
#> 14                                                                                                                                                         Overall Response
#> 15                                                                                                                                                       Survival Post-HSCT
#> 16                                                                                                                                          Cumulative Duration of Response
#> 17                                                                                                                                                 Time to Overall Response
#> 18                                                                                                                                             Durability of First Response
#> 19                                                                                                                                                    Glucocortoid Tapering
#> 20                                                                                                                                                        Survival Pre-HSCT
#> 21                                                                                                                                                         Overall Survival
#> 22                                                                                                                                                         Overall Response
#> 23                                                                                                                                                       Survival Post-HSCT
#> 24                                                                                                                                          Cumulative Duration of Response
#> 25                                                                                                                                                 Time to Overall Response
#> 26                                                                                                                                             Durability of First Response
#> 27                                                                                                                                                    Glucocortoid Tapering
#> 28                                                                                                                                                        Survival Pre-HSCT
#> 29                                                                                                                                                         Overall Survival
#> 30                                                                                                                                                         Overall Response
#> 31                                                                                                                                                       Survival Post-HSCT
#> 32                                                                                                                                          Cumulative Duration of Response
#> 33                                                                                                                                                 Time to Overall Response
#> 34                                                                                                                                             Durability of First Response
#> 35                                                                                                                                                    Glucocortoid Tapering
#> 36                                                                                                                                                        Survival Pre-HSCT
#> 37                                                                                                                                                         Overall Survival
#> 38                                                                                                                                                         Overall Response
#> 39                                                                                                                                                       Survival Post-HSCT
#> 40                                                                                                                                          Cumulative Duration of Response
#> 41                                                                                                                                                 Time to Overall Response
#> 42                                                                                                                                             Durability of First Response
#> 43                                                                                                                                                    Glucocortoid Tapering
#> 44                                                                                                                                                        Survival Pre-HSCT
#> 45                                                                                                                                                         Overall Survival
#> 46                                                                                                                                                         Overall Response
#> 47                                                                                                                                                       Survival Post-HSCT
#> 48                                                                                                                                          Cumulative Duration of Response
#> 49                                                                                                                                                 Time to Overall Response
#> 50                                                                                                                                             Durability of First Response
#> 51                                                                                                                                                    Glucocortoid Tapering
#> 52                                                                                                                                                        Survival Pre-HSCT
#> 53                                                                                                                                                         Overall Survival
#> 54                                                                                                                                                         Overall Response
#> 55                                                                                                                                                       Survival Post-HSCT
#> 56                                                                                                                                          Cumulative Duration of Response
#> 57                                                          Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 58                                                          Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 59                                                                                                                 Annualized Number of Spontaneous Joint Bleeding Episodes
#> 60                                                 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 61                                                                                                                                      Total Number of Exposure Days (EDs)
#> 62                                                                  Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 63                                                                                                  Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 64                                                                                            Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 65                                                                                                                    Change From Baseline in rFVIIIFc Incremental Recovery
#> 66                                                                                                     Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 67                                                          Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 68                                                          Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 69                                                                                                                 Annualized Number of Spontaneous Joint Bleeding Episodes
#> 70                                                 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 71                                                                                                                                      Total Number of Exposure Days (EDs)
#> 72                                                                  Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 73                                                                                                  Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 74                                                                                            Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 75                                                                                                                    Change From Baseline in rFVIIIFc Incremental Recovery
#> 76                                                                                                     Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 77                                                          Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 78                                                          Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 79                                                                                                                 Annualized Number of Spontaneous Joint Bleeding Episodes
#> 80                                                 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 81                                                                                                                                      Total Number of Exposure Days (EDs)
#> 82                                                                  Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 83                                                                                                  Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 84                                                                                            Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 85                                                                                                                    Change From Baseline in rFVIIIFc Incremental Recovery
#> 86                                                                                                     Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 87                                                          Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 88                                                          Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 89                                                                                                                 Annualized Number of Spontaneous Joint Bleeding Episodes
#> 90                                                 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 91                                                                                                                                      Total Number of Exposure Days (EDs)
#> 92                                                                  Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 93                                                                                                  Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 94                                                                                            Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 95                                                                                                                    Change From Baseline in rFVIIIFc Incremental Recovery
#> 96                                                                                                     Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 97                                                          Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 98                                                          Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 99                                                                                                                 Annualized Number of Spontaneous Joint Bleeding Episodes
#> 100                                                Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 101                                                                                                                                     Total Number of Exposure Days (EDs)
#> 102                                                                 Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 103                                                                                                 Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 104                                                                                           Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 105                                                                                                                   Change From Baseline in rFVIIIFc Incremental Recovery
#> 106                                                                                                    Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 107                                                         Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 108                                                         Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 109                                                                                                                Annualized Number of Spontaneous Joint Bleeding Episodes
#> 110                                                Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 111                                                                                                                                     Total Number of Exposure Days (EDs)
#> 112                                                                 Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 113                                                                                                 Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 114                                                                                           Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 115                                                                                                                   Change From Baseline in rFVIIIFc Incremental Recovery
#> 116                                                                                                    Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 117                                                         Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 118                                                         Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 119                                                                                                                Annualized Number of Spontaneous Joint Bleeding Episodes
#> 120                                                Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 121                                                                                                                                     Total Number of Exposure Days (EDs)
#> 122                                                                 Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 123                                                                                                 Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 124                                                                                           Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 125                                                                                                                   Change From Baseline in rFVIIIFc Incremental Recovery
#> 126                                                                                                    Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 127                                                         Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 128                                                         Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 129                                                                                                                Annualized Number of Spontaneous Joint Bleeding Episodes
#> 130                                                Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 131                                                                                                                                     Total Number of Exposure Days (EDs)
#> 132                                                                 Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 133                                                                                                 Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 134                                                                                           Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 135                                                                                                                   Change From Baseline in rFVIIIFc Incremental Recovery
#> 136                                                                                                    Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 137                                                         Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 138                                                         Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 139                                                                                                                Annualized Number of Spontaneous Joint Bleeding Episodes
#> 140                                                Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 141                                                                                                                                     Total Number of Exposure Days (EDs)
#> 142                                                                 Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 143                                                                                                 Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 144                                                                                           Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 145                                                                                                                   Change From Baseline in rFVIIIFc Incremental Recovery
#> 146                                                                                                    Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 147                                                         Percentage of Subjects With Confirmed Inhibitor Development as Measured by the Nijmegen-Modified Bethesda Assay
#> 148                                                         Annualized Number of Bleeding Episodes (Spontaneous and Traumatic) per Subject (Annualized Bleeding Rate [ABR])
#> 149                                                                                                                Annualized Number of Spontaneous Joint Bleeding Episodes
#> 150                                                Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 151                                                                                                                                     Total Number of Exposure Days (EDs)
#> 152                                                                 Total Annualized rFVIIIFc Consumption per Subject for the Prevention and Treatment of Bleeding Episodes
#> 153                                                                                                 Number of Injections of rFVIIIFc Required to Resolve a Bleeding Episode
#> 154                                                                                           Average Dose per Injection of rFVIIIFc Required to Resolve a Bleeding Episode
#> 155                                                                                                                   Change From Baseline in rFVIIIFc Incremental Recovery
#> 156                                                                                                    Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 157                                                       Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 6 Months Corrected age (CA)
#> 158                                                                      Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 12 Months CA
#> 159                                                                      Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 20 Months CA
#> 160                                                                      Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 24 Months CA
#> 161                                                                     Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 4.75 Years CA
#> 162                                                                        Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 5 Years CA
#> 163                    Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 12 Months CA
#> 164                    Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 24 Months CA
#> 165                      Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 5-Years CA
#> 166                                                                                                                   Number of Participants With Nystagmus at 12 Months CA
#> 167                                                                                                                   Number of Participants With Nystagmus at 24 Months CA
#> 168                                                                                                                     Number of Participants With Nystagmus at 5 Years CA
#> 169                                                                                                   Refraction With Cycloplegia as Assessed by Retinoscopy at 6 Months CA
#> 170                                                                                                   Refraction With Cycloplegia as Assessed by Retinoscopy at 12 Month CA
#> 171                                                                                                   Refraction With Cycloplegia as Assessed by Retinoscopy at 20 Month CA
#> 172                                                                                                 Refraction With Cycloplegia as Assessed by Retinoscopy at 4.75 Years CA
#> 173                                                                             Number of Participants With Stereoacuity as Assessed With the Lang Stereotest At 5 Years CA
#> 174                                                                                                                        Number of Participants With Adverse Events (AEs)
#> 175                                                                                                                             Change From Baseline in Body Weight Z-score
#> 176                                                                                                                                  Change From Baseline in Height Z-score
#> 177                                                                                                                      Change From Baseline in Head Circumference Z-score
#> 178 Change from Baseline (12 Months CA) in Cognitive Development as Assessed by Bayley Scales of Infant and Toddler Development (BSID-III) Composite Scores at 24 Months CA
#> 179                                           Cognitive Development as Assessed by Wechsler Preschool and Primary Scale of Intelligence (WPPSI-IV) Full Scale at 5 Years CA
#> 180                                                                                                               Number of Participants With Abnormal Physical Examination
#> 181                                                                   Number of Participants Diagnosed With Cerebral Palsy (CP) by Neurological Examination at 24 Months CA
#> 182                                                        Change From Baseline (6 Months CA) in Child Behavior as Assessed by Vineland Adaptive Behaviour Scales (VABS-II)
#> 183                                                                                                Number of Participants With Normal and Abnormal Hearing Screening Status
#> 184                                        Number of Participants With Child Behaviour as Assessed by Child Behaviour Checklist (CBCL) Based on T-Score Clinical Categories
#> 185                                                      Child Behavior as Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS) Based on Total Score
#> 186                                                                                                                         Number of Participants With Pulmonary Morbidity
#> 187                                                                             Child Behavior as Assessed by Social Communication Questionnaire (SCQ) Based on Total Score
#> 188                                                                                                                             Number of Participants With Survival Status
#> 189                                                                 Change From Baseline (3 Months CA) in Pediatric Quality of Life Inventory (PedsQL™) Scale: Infant Scale
#> 190                                        Change From Baseline (24 Months CA) in Pediatric Quality of Life Inventory (PedsQL™) Scale: Generic Core Scale (GCS) Total Score
#> 191                                                       Number of Participants With Health Status Measured by the Health Status Classification System-Preschool (HSCS-PS)
#> 192                                                                                                 Health Status Measured by the Health Utilities Index (HUI) Mark 2 and 3
#> 193                                                                                                                                         Health Care Resource Use (HCRU)
#> 194                                                                                       Health Care Resource Utilization (HCRU): Number of Visits to Emergency Department
#> 195                                                                                                    Health Care Resource Utilization (HCRU): Duration of Hospitalization
#> 196                                            Health Care Resource Utilization (HCRU): Number of Participants who Required Prescription Eyeglasses and Educational Support
#> 197                                                       Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 6 Months Corrected age (CA)
#> 198                                                                      Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 12 Months CA
#> 199                                                                      Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 20 Months CA
#> 200                                                                      Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 24 Months CA
#> 201                                                                     Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 4.75 Years CA
#> 202                                                                        Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 5 Years CA
#> 203                    Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 12 Months CA
#> 204                    Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 24 Months CA
#> 205                      Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 5-Years CA
#> 206                                                                                                                   Number of Participants With Nystagmus at 12 Months CA
#> 207                                                                                                                   Number of Participants With Nystagmus at 24 Months CA
#> 208                                                                                                                     Number of Participants With Nystagmus at 5 Years CA
#> 209                                                                                                   Refraction With Cycloplegia as Assessed by Retinoscopy at 6 Months CA
#> 210                                                                                                   Refraction With Cycloplegia as Assessed by Retinoscopy at 12 Month CA
#> 211                                                                                                   Refraction With Cycloplegia as Assessed by Retinoscopy at 20 Month CA
#> 212                                                                                                 Refraction With Cycloplegia as Assessed by Retinoscopy at 4.75 Years CA
#> 213                                                                             Number of Participants With Stereoacuity as Assessed With the Lang Stereotest At 5 Years CA
#> 214                                                                                                                        Number of Participants With Adverse Events (AEs)
#> 215                                                                                                                             Change From Baseline in Body Weight Z-score
#> 216                                                                                                                                  Change From Baseline in Height Z-score
#> 217                                                                                                                      Change From Baseline in Head Circumference Z-score
#> 218 Change from Baseline (12 Months CA) in Cognitive Development as Assessed by Bayley Scales of Infant and Toddler Development (BSID-III) Composite Scores at 24 Months CA
#> 219                                           Cognitive Development as Assessed by Wechsler Preschool and Primary Scale of Intelligence (WPPSI-IV) Full Scale at 5 Years CA
#> 220                                                                                                               Number of Participants With Abnormal Physical Examination
#> 221                                                                   Number of Participants Diagnosed With Cerebral Palsy (CP) by Neurological Examination at 24 Months CA
#> 222                                                        Change From Baseline (6 Months CA) in Child Behavior as Assessed by Vineland Adaptive Behaviour Scales (VABS-II)
#> 223                                                                                                Number of Participants With Normal and Abnormal Hearing Screening Status
#> 224                                        Number of Participants With Child Behaviour as Assessed by Child Behaviour Checklist (CBCL) Based on T-Score Clinical Categories
#> 225                                                      Child Behavior as Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale (ADHD-RS) Based on Total Score
#> 226                                                                                                                         Number of Participants With Pulmonary Morbidity
#> 227                                                                             Child Behavior as Assessed by Social Communication Questionnaire (SCQ) Based on Total Score
#> 228                                                                                                                             Number of Participants With Survival Status
#> 229                                                                 Change From Baseline (3 Months CA) in Pediatric Quality of Life Inventory (PedsQL™) Scale: Infant Scale
#> 230                                        Change From Baseline (24 Months CA) in Pediatric Quality of Life Inventory (PedsQL™) Scale: Generic Core Scale (GCS) Total Score
#> 231                                                       Number of Participants With Health Status Measured by the Health Status Classification System-Preschool (HSCS-PS)
#> 232                                                                                                 Health Status Measured by the Health Utilities Index (HUI) Mark 2 and 3
#> 233                                                                                                                                         Health Care Resource Use (HCRU)
#> 234                                                                                       Health Care Resource Utilization (HCRU): Number of Visits to Emergency Department
#> 235                                                                                                    Health Care Resource Utilization (HCRU): Duration of Hospitalization
#> 236                                            Health Care Resource Utilization (HCRU): Number of Participants who Required Prescription Eyeglasses and Educational Support
#> 237                                                       Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 6 Months Corrected age (CA)
#> 238                                                                      Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 12 Months CA
#> 239                                                                      Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 20 Months CA
#> 240                                                                      Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 24 Months CA
#> 241                                                                     Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 4.75 Years CA
#> 242                                                                        Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 5 Years CA
#> 243                    Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 12 Months CA
#> 244                    Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 24 Months CA
#> 245                      Number of Participants With Oculomotor Examination (Motility) and Ocular Alignment (Assessed by Corneal Light Reflex and Cover Test) at 5-Years CA
#> 246                                                                                                                   Number of Participants With Nystagmus at 12 Months CA
#> 247                                                                                                                   Number of Participants With Nystagmus at 24 Months CA
#> 248                                                                                                                     Number of Participants With Nystagmus at 5 Years CA
#> 249                                                                                                   Refraction With Cycloplegia as Assessed by Retinoscopy at 6 Months CA
#> 250                                                                                                   Refraction With Cycloplegia as Assessed by Retinoscopy at 12 Month CA
#>     item
#> 1      1
#> 2      2
#> 3      3
#> 4      4
#> 5      5
#> 6      6
#> 7      7
#> 8      8
#> 9      1
#> 10     2
#> 11     3
#> 12     4
#> 13     5
#> 14     6
#> 15     7
#> 16     8
#> 17     1
#> 18     2
#> 19     3
#> 20     4
#> 21     5
#> 22     6
#> 23     7
#> 24     8
#> 25     1
#> 26     2
#> 27     3
#> 28     4
#> 29     5
#> 30     6
#> 31     7
#> 32     8
#> 33     1
#> 34     2
#> 35     3
#> 36     4
#> 37     5
#> 38     6
#> 39     7
#> 40     8
#> 41     1
#> 42     2
#> 43     3
#> 44     4
#> 45     5
#> 46     6
#> 47     7
#> 48     8
#> 49     1
#> 50     2
#> 51     3
#> 52     4
#> 53     5
#> 54     6
#> 55     7
#> 56     8
#> 57     1
#> 58     2
#> 59     3
#> 60     4
#> 61     5
#> 62     6
#> 63     7
#> 64     8
#> 65     9
#> 66    10
#> 67     1
#> 68     2
#> 69     3
#> 70     4
#> 71     5
#> 72     6
#> 73     7
#> 74     8
#> 75     9
#> 76    10
#> 77     1
#> 78     2
#> 79     3
#> 80     4
#> 81     5
#> 82     6
#> 83     7
#> 84     8
#> 85     9
#> 86    10
#> 87     1
#> 88     2
#> 89     3
#> 90     4
#> 91     5
#> 92     6
#> 93     7
#> 94     8
#> 95     9
#> 96    10
#> 97     1
#> 98     2
#> 99     3
#> 100    4
#> 101    5
#> 102    6
#> 103    7
#> 104    8
#> 105    9
#> 106   10
#> 107    1
#> 108    2
#> 109    3
#> 110    4
#> 111    5
#> 112    6
#> 113    7
#> 114    8
#> 115    9
#> 116   10
#> 117    1
#> 118    2
#> 119    3
#> 120    4
#> 121    5
#> 122    6
#> 123    7
#> 124    8
#> 125    9
#> 126   10
#> 127    1
#> 128    2
#> 129    3
#> 130    4
#> 131    5
#> 132    6
#> 133    7
#> 134    8
#> 135    9
#> 136   10
#> 137    1
#> 138    2
#> 139    3
#> 140    4
#> 141    5
#> 142    6
#> 143    7
#> 144    8
#> 145    9
#> 146   10
#> 147    1
#> 148    2
#> 149    3
#> 150    4
#> 151    5
#> 152    6
#> 153    7
#> 154    8
#> 155    9
#> 156   10
#> 157    1
#> 158    2
#> 159    3
#> 160    4
#> 161    5
#> 162    6
#> 163    7
#> 164    8
#> 165    9
#> 166   10
#> 167   11
#> 168   12
#> 169   13
#> 170   14
#> 171   15
#> 172   16
#> 173   17
#> 174   18
#> 175   19
#> 176   20
#> 177   21
#> 178   22
#> 179   23
#> 180   24
#> 181   25
#> 182   26
#> 183   27
#> 184   28
#> 185   29
#> 186   30
#> 187   31
#> 188   32
#> 189   33
#> 190   34
#> 191   35
#> 192   36
#> 193   37
#> 194   38
#> 195   39
#> 196   40
#> 197    1
#> 198    2
#> 199    3
#> 200    4
#> 201    5
#> 202    6
#> 203    7
#> 204    8
#> 205    9
#> 206   10
#> 207   11
#> 208   12
#> 209   13
#> 210   14
#> 211   15
#> 212   16
#> 213   17
#> 214   18
#> 215   19
#> 216   20
#> 217   21
#> 218   22
#> 219   23
#> 220   24
#> 221   25
#> 222   26
#> 223   27
#> 224   28
#> 225   29
#> 226   30
#> 227   31
#> 228   32
#> 229   33
#> 230   34
#> 231   35
#> 232   36
#> 233   37
#> 234   38
#> 235   39
#> 236   40
#> 237    1
#> 238    2
#> 239    3
#> 240    4
#> 241    5
#> 242    6
#> 243    7
#> 244    8
#> 245    9
#> 246   10
#> 247   11
#> 248   12
#> 249   13
#> 250   14
#>  [ reached 'max' / getOption("max.print") -- omitted 143 rows ]